How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Secukinumab for treating non-radiographic axial spondyloarthritis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about secukinumab

Marketing authorisation indication

2.1 Secukinumab (Cosentyx, Novartis) is 'indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is in the summary of product characteristics.

Price

2.3 The list price is £1,218.78 for 2 pre-filled pens or syringes containing 150 mg per 1 ml solution (excluding VAT, BNF online accessed March 2021). Annual cost of treatment for the first year is £9,750.24 and subsequent years is £7,312.68. The company has a commercial arrangement (simple discount patient access scheme). This makes secukinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.